Recently, a large number of pharmaceutical companies are laying out in the field of large health

With the gradual improvement of living standards, people's demand for health services is growing, which further promotes the development of
the health industry.
Incomplete statistics show that the market size of the large health industry has reached 7 trillion yuan in 2020, and under the background of the support of many favorable policies and the continuous increase of capital, it is predicted that the market will exceed 8 trillion yuan
in 2022.
At present, with the state positioning the health industry as a pillar industry of the national economy, consumers, enterprises, etc.
have become more deeply rooted in the concept of general health
.
Taking pharmaceutical companies as an example, under the background of the accelerated development of the domestic pharmaceutical industry, more and more pharmaceutical companies have seen the opportunities brought by the big health industry and are accelerating their pace to enter the big health industry
.
Recently, many pharmaceutical companies have announced that they will launch new actions
in the field of general health.
On November 11, Tailong Pharmaceutical issued a capital increase announcement, intending to increase the capital of Tailong Health by 220 million yuan in cash (including an increase of 29.
2 million yuan in registered capital and an increase in capital reserve of 191 million yuan).

After the completion of this capital increase, the registered capital of Tailong Health will increase from 161 million yuan to 190 million yuan, and it will still be a wholly-owned subsidiary
of the company.
According to the announcement, Tailong Health is the professional investment platform of Tailong Pharmaceutical, which aims to effectively connect the company's medium- and long-term strategic development plan, explore high-quality targets in the field of medicine and health, and accelerate the layout of the upstream and downstream of the industrial chain by investing in industrial funds in the direction of medicine and health, so as to enhance the company's overall competitiveness and achieve capital appreciation
.
On the evening of November 7, Puli Pharmaceutical issued an announcement that due to the company's business development needs, in order to realize the company's life-based health business layout, the company intends to use its own funds to invest in the establishment of a wholly-owned subsidiary Zhejiang Puli Health Technology Co.
, Ltd.
, with a registered capital of 10 million yuan
.
According to the announcement information, Puli Health is located in Linping District, Hangzhou City, Zhejiang Province, with a registered capital of 10 million yuan, and its business scope includes: the production of formula food for special medical purposes; health food production; food sales; sales of health care products; Internet sales, etc
.
The relevant person in charge of Puli Pharmaceutical said: "At present, the company has some functional foods under research, and the initial stage of Puli Health is mainly based on the production and sales of raw materials and a series of products of the company's functional foods, health care products and functional cosmetics, and will gradually expand functional health products
.
Zhu's Pharmaceutical Group also recently released its new health food brand COZY Kaizi, and announced four products
: whiskey flavored jelly, taurine jelly, aminobutyric acid flavored drinks and lutein ester-flavored beverages 。 According to the person in charge of the enterprise, the incubated COZY Kaizi brand is an important part of the group's creation of the whole industry layout of big health products, mainly for Z generation consumers, with health, comfort and portability as the selling points, highlighting fashion and trendiness in packaging design, and targeting the pain points of young consumers such as insomnia, fatigue, and eye sub-health problems in product functions, which can extend more use scenarios
.
Industry analysts believe that the layout of the large health industry has become one of the trends in the
pharmaceutical industry.
In the future, under the influence of factors such as the improvement of policies, the continuous improvement of China's economic growth and consumption capacity, and the continuous intensification of medical care caused by the aging of the population, the big health industry will accelerate its development in China and is expected to become a new growth point
of the national economy.
In this context, pharmaceutical companies deployed in this field are expected to usher in more opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.